CordenPharma Increases US Peptide Manufacturing Capacity

Published on: 

CordenPharma added a 3000-L solid-phase peptide synthesis vessel to its GMP API facility in Boulder, CO.

CordenPharma expanded its solid-phase peptide manufacturing capacity at its CordenPharma Colorado GMP API facility in Boulder, CO. The expansion was made to accommodate a large spike in the demand for peptide APIs, and to continue an overall growth strategy, the company said in a July 7, 2020 press release. 

“With the addition of this extra-large 3000-L SPPS [Solid-Phase Peptide Synthesis] vessel, our assembly-time, capacity, and flexibility has been significantly increased. … This new asset gives us the ability to manufacture a complex long peptide with a 400 kg output per single batch. Our team in Colorado aims to utilize this new capacity to conduct validation campaigns designed to support customer projects with a global impact,” said Matthieu Giraud, director of the Global Peptides, Lipids, and Carbohydrates Platform at CordenPharma, in the press release. 

The facility already had large-scale capability, with a 10,000-L SPPS vessel and a 100-cm high-pressure reverse phase purification column. The company said in the press release that it can develop and manufacture APIs from laboratory scale to commercialization at ton scale, and that the purification of the final peptide is performed at any scale in columns ranging from 5 cm to 100 cm. 


Source: CordenPharma